1-3 of 3
Junlong Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia

Michael R. Verneris, Qiufei Ma, Jie Zhang, Amy Keating, Ranjan Tiwari, Junlong Li, Hongbo Yang, Abhijit Agarwal, Lida Pacaud
Journal: Blood Advances
Blood Adv (2021) 5 (23): 5387–5395.
https://doi.org/10.1182/bloodadvances.2020004045
Published: 2021
Journal Articles

Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Richard T. Maziarz, Stephen J. Schuster, Vadim V. Romanov, Elisha S. Rusch, Junlong Li, James E. Signorovitch, David G. Maloney, Frederick L. Locke
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1440–1447.
https://doi.org/10.1182/bloodadvances.2019001305
Published: 2020
Includes: Supplemental data
Journal Articles

Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial

Clinical Trials & Observations
Stephen J. Schuster, Richard T. Maziarz, Elisha S. Rusch, Junlong Li, James E. Signorovitch, Vadim V. Romanov, Frederick L. Locke, David G. Maloney
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1432–1439.
https://doi.org/10.1182/bloodadvances.2019001304
Published: 2020
Includes: Supplemental data